Year 2024 / Volume 116 / Number 11
Original
Ultrasound transmural healing correlates with higher adalimumab drug concentration in Crohn’s disease only in the short-term

606-612

DOI: 10.17235/reed.2024.10489/2024

José Ramón Lorente, José María Paredes, Pilar Llopis, Tomás Ripollés, Alba Voces, Ángela Algarra, Carmina Asencio, Patricia Latorre, Nadia Moreno, Antonio López-Serrano, Eduardo Moreno-Osset,

Abstract
Background: anti-TNF drugs have revolutionized the treatment of Crohn’s disease (CD) and have set new therapeutic targets. A direct correlation between anti-TNF trough levels and endoscopic healing in inflammatory bowel disease (IBD) patients has been established, but the association between drug levels and transmural healing assessed by ultrasound is not yet clearly defined. Aims: to evaluate the correlation between the serum concentration of adalimumab (ADA) and sonographic transmural healing in CD patients at different times during follow-up. Methods: in this retrospective, cross-sectional study, all patients with CD who were undergoing treatment with ADA in our center were included. Intestinal ultrasound (IUS) was performed before the initiation of the drug and for response monitoring. ADA serum-trough levels were compared between patients with and without transmural healing at different periods of time. Results: ninety-two patients were included, and all patients showed signs of inflammatory activity in the baseline IUS. During IUS monitoring of the response to ADA, 34 (34.8 %) patients presented transmural healing. Among patients in the first year of treatment, those with sonographic healing showed higher median levels than patients without transmural healing (12.0 µg/ml vs 9.3 µg/ml, respectively; p = 0.007). There was no correlation between ADA levels and sonographic healing in patients undergoing treatment for over a year. Conclusions: higher ADA trough levels correlated with transmural healing with ultrasound during the first year of treatment. This correlation was not found after one year of treatment.
Lay Summary
Background: Anti-TNF drugs have revolutionized the treatment of Crohn’s disease and have set new therapeutic targets. It remains unclear whether higher plasma drug levels are associated with sonographic transmural healing. Aims: To evaluate the correlation between the serum concentration of adalimumab and sonographic transmural healing in Crohn’s disease patients at different times during follow-up. Methods: A retrospective study which included all patients with Crohn’s undergoing adalimumab in our center, performing plasma drug concentration and intestinal ultrasound before and after the initiation of the drug. Results: A third of patients showed transmural healing in the follow-up ultrasound. Patients in the first year of treatment showed higher drug levels when they had achieved transmural healing. This relationship was not found in patients undergoing treatment for over a year. Conclusions: Higher adalimumab serum levels were corelated with transmural healing with ultrasound during the first year of treatment. This correlation was not found after one year of treatment.
Share Button
New comment
Comments
No comments for this article
References
1. Marsal J, Barreiro-de Acosta M, Blumenstein I, et al. Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease. Front Med 2022;9:897-936.
2. Wilkens R, Novak KL, Maaser C, et al. Relevance of monitoring transmural disease activity in patients with Crohn´s disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:1-18.
3. Paredes JM, Moreno N, Latorre P, et al. Clinical impact of sonographic transmural healing after anti-TNF antibody treatment in patients with Crohn´s disease. Dig Dis Sci 2019;64:2600-2606.
4. Yarur AJ, Jain A, Hauenstein SI, et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22(2):409-15.
5. Ungar B, Ben-Shatach Z, Selinger L, et al. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn´s disease. United European Gastroenterol J 2020;8:167-174.
6. Han ZM, Elodie WH, Yan LH, et al. Correlation between ultrasonographic response and anti-tumor necrosis factor drug levels in Crohn's disease. Ther Drug Monit. 2022;44:659-664.
7. Vaughan R, Murphy E, Nalder M, et al. Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023;29(7):1080-1088.
8. Takenaka K, Kawamoto A, Kitazume Y, et al. Transmural Remission Characterized by High Biologic Concentrations Demonstrates Better Prognosis in Crohn's Disease. J Crohns Colitis. 2023;17(6):855-862.
9. Bossuyt P, Dreesen E, Rimola J, et al. Infliximab exposure associates with radiologic evidence of healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2021;19:947-954.
10. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6.
11. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol 2010;8:357-363.
12. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570-1583.
13. Patriquin HB, Garcier JM, Lafortune M, et al. Appendicitis in children and young adults: Doppler sonographic-pathologic correlation. AJR Am J Roentgenol. 1996;166:629–633.
14. Ripollés T, Paredes JM, Martínez-Pérez MJ, et al. Ultrasonographic Changes at 12 Weeks of Anti-TNF Drugs Predict 1-year Sonographic Response and Clinical Outcome in Crohn's Disease: A Multicenter Study. Inflamm Bowel Dis. 2016;22:2465-73.
15. Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology 2017;153:835-857.
16. Reenaers C, Bossuyt P, Hindryckx P, et al. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J 2018;6:1117- 1125.
17- Choi SY, Kwon Y, Choi S, et al. Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn's disease. Front Immunol. 2023;14:1192827.
18- Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-53.
19- Schultheiss JPD, Mahmoud R, Louwers JM, et al. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2021;54:1298-1308.
20- Alsoud D, Verstockt B, Vermeire S. Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era. Aliment Pharmacol Ther. 2022;55:885-886.
21- Chanchlani N, Lin S, Bewshea C, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol. 2024;9:521-538.
Related articles

Letter

Treatment with hyperbaric oxygen in a Crohn’s disease patient

DOI: 10.17235/reed.2024.10166/2023

Letter

Coincidental oral lesions in Crohn’s disease

DOI: 10.17235/reed.2023.9992/2023

Letter

Duodenal stenosis surgical treatment in Crohn’s disease

DOI: 10.17235/reed.2023.9521/2023

Digestive Diseases Image

Peristomal cutaneous Crohn's disease by contiguity

DOI: 10.17235/reed.2022.8909/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Crohn’s disease in patients treated with etanercept

DOI: 10.17235/reed.2019.6554/2019

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Letter to the Editor

Adnexal localization of Crohn’s disease and recurrent massive ovary cysts

DOI: 10.17235/reed.2016.4301/2016

Case Report

Metastatic Crohn’s disease in pediatrics

DOI: 10.17235/reed.2016.3948/2015

Letter to the Editor

Crohn’s disease and Sweet’s syndrome: A debut together

DOI: 10.17235/reed.2015.3842/2015

Case Report

Ovarian involvement in Crohn´s disease: A rare complication

DOI: 10.17235/reed.2015.3764/2015

Citation tools
Lorente J, Paredes J, Llopis P, Ripollés T, Voces A, Algarra Á, et all. Ultrasound transmural healing correlates with higher adalimumab drug concentration in Crohn’s disease only in the short-term. 10489/2024


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 59 visits.
This article has been downloaded 14 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 17/04/2024

Accepted: 29/07/2024

Online First: 01/08/2024

Published: 11/11/2024

Article revision time: 94 days

Article Online First time: 106 days

Article editing time: 208 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology